Good morning Mr. Chairman and committee members.
My name is Rachelle. I’m a patient advocate and member of the Global Healthy Living Foundation’s 50-State Network. I have been a resident of Chesterfield, Michigan for the past 12 years, but I am a lifelong Michigander. My legislators are Representative Andrea LaFontaine and Senator Jack Brandenburg. I want to thank you for allowing me to speak today about House Bill 4812.
The existence of CT-P13, a biosimilar version of infliximab (Remsima), and its recommended approval on Tuesday by the FDA Arthritis Advisory Committee, is reason to celebrate.
Salem resident Joni Johnston testified to the Missouri General Assembly’s House Emerging Issues Committee Jan. 20.
The committee will discuss biologics license application (BLA) 125544, for CT-P13, a
proposed biosimilar to Janssen Biotech Inc.’s REMICADE (infliximab), submitted by Celltrion,
Chairman Pitts and Ranking Member Green,
On behalf of the Global Healthy Living Foundation, I want to thank you both for your leadership and commitment to ensure the appropriate implementation of the Biologics …